Literature DB >> 27433045

Peripheral ulcerative keratitis associated with chronic malabsorption syndrome and miliary tuberculosis in a child.

Mahmood Dhahir Al-Mendalawi1.   

Abstract

Entities:  

Year:  2016        PMID: 27433045      PMCID: PMC4932798          DOI: 10.4103/0974-620X.184536

Source DB:  PubMed          Journal:  Oman J Ophthalmol        ISSN: 0974-620X


× No keyword cloud information.
Sir, With reference to the interesting case report by Arora et al.,[1] there are three prevailing health threats in India. Giardiasis is a significant cause of diarrheal disease, and it is associated with a significant morbidity in children and adults. The available data pointed out to a substantial prevalence rate of giardia infection in patients with diarrhea in India (0.4–70%).[2] Tuberculosis (TB) is another public health problem of great significance in India. The recently published data indicated an alarming increase in the prevalence of multidrug-resistant TB (P < 0.001) by 12% (4.7% in 2000–19.8% in 2012).[3] Human immunodeficiency virus (HIV) infection is still imposing a great health burden in India. The recently published data showed that the estimated adult HIV prevalence retained a declining trend in India, following its peak in 2002 at a level of 0.41% (within bounds 0.35–0.47%). By 2010 and 2011, it leveled at estimates of 0.28% (0.24–0.34%) and 0.27% (0.22–0.33%), respectively.[4] It is obvious that there are numerous ophthalmic manifestations in patients with HIV infection in the era of highly active antiretroviral therapy, where 7% of the patients in India were found to present with ophthalmological features as the initial manifestation of HIV infection. Moreover, most (70%) of the ophthalmic manifestations of HIV infection were presented when CD4 count was <200 cells/μL.[5] I presume that the constellation of peripheral ulcerative keratitis (PUK), chronic malabsorption syndrome due to giardiasis, and miliary TB in the case in question should alert the authors to the underlying immune deficiency status, particularly HIV infection. Hence, the diagnostic algorithm of CD4 count and viral overload measurements was solicited to be contemplated by the authors. If that diagnostic algorithm was done and it disclosed a concomitant HIV infection, the case in question could be regarded as a novel case report, as concurrent occurrence of the three infections in a patient with PUK has never been reported in the literature.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

Review 1.  Giardiasis: a review on assemblage distribution and epidemiology in India.

Authors:  Shakti Laishram; Gagandeep Kang; Sitara Swarna Rao Ajjampur
Journal:  Indian J Gastroenterol       Date:  2012-02-07

2.  Ophthalmic manifestations of HIV infections in India in the era of HAART: analysis of 100 consecutive patients evaluated at a tertiary eye care center in India.

Authors:  Sujit Gharai; Pradeep Venkatesh; Satpal Garg; S K Sharma; Rajpal Vohra
Journal:  Ophthalmic Epidemiol       Date:  2008 Jul-Aug       Impact factor: 1.648

3.  Peripheral ulcerative keratitis associated with chronic malabsorption syndrome and miliary tuberculosis in a child.

Authors:  Tarun Arora; Namrata Sharma; Adarsh Shashni; Jeewan S Titiyal
Journal:  Oman J Ophthalmol       Date:  2015 Sep-Dec

4.  Modelling and estimation of HIV prevalence and number of people living with HIV in India, 2010-2011.

Authors:  Yujwal Raj; Damodar Sahu; Arvind Pandey; S Venkatesh; Dcs Reddy; Taoufik Bakkali; Chinmoyee Das; Kh Jitenkumar Singh; Shashi Kant; M Bhattacharya; John Stover; Ugra Mohan Jha; Pradeep Kumar; Ram Manohar Mishra; Nalini Chandra; B K Gulati; Sharad Mathur; Deepika Joshi; L Chavan
Journal:  Int J STD AIDS       Date:  2015-10-22       Impact factor: 1.359

5.  Multidrug-resistant pulmonary & extrapulmonary tuberculosis: A 13 years retrospective hospital-based analysis.

Authors:  Reena Raveendran; Jaswinder Kaur Oberoi; Chand Wattal
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.